MaxCyte, Inc. (LON:MXCT – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as GBX 200 ($2.58) and last traded at GBX 205.68 ($2.65), with a volume of 26796 shares. The stock had previously closed at GBX 213 ($2.75).
MaxCyte Price Performance
The company has a debt-to-equity ratio of 8.59, a current ratio of 9.81 and a quick ratio of 14.38. The firm has a market capitalization of £257.41 million, a P/E ratio of -7.15 and a beta of 1.13. The company’s 50 day moving average price is GBX 286.49 and its 200 day moving average price is GBX 301.18.
MaxCyte Company Profile
MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.
Featured Stories
- Five stocks we like better than MaxCyte
- What Are Trending Stocks? Trending Stocks Explained
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- Top Stocks Investing in 5G Technology
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- How to Plot Fibonacci Price Inflection Levels
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
